NCT03026933View on ClinicalTrials.gov

Evaluate the Efficacy and Safety of KI1107 in Patients Whose TG Level is Not Adequately Controlled With Rosuvastatin Calcium Monotherapy While LDL-C is Properly Controlled

PHASE3CompletedINTERVENTIONAL
Enrollment

215

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Dyslipidemias
Interventions
DRUG

KI1107 4 Capsules, QD

KI1107 4 Capsules

DRUG

Rosuvastatin Calcium 20 MG, QD

Rosuvastatin Calcium 20mg, QD

Sponsors
All Listed Sponsors
lead

Kuhnil Pharmaceutical Co., Ltd.

INDUSTRY

NCT03026933 - Evaluate the Efficacy and Safety of KI1107 in Patients Whose TG Level is Not Adequately Controlled With Rosuvastatin Calcium Monotherapy While LDL-C is Properly Controlled | Biotech Hunter | Biotech Hunter